The quest for understanding and managing the long-term effects of COVID-19, often referred to as Long COVID or post-COVID-19 condition (PCC), remains an active research area. Recent findings highlighted angiopoietin-1 (ANG-1) and p-selectin (P-SEL) as potential diagnostic markers, but validation is essential, given the inconsistency in COVID-19 biomarker studies. Leveraging the biobanque québécoise de la COVID-19 (BQC19) biobank, we analyzed the data of 249 participants. Both ANG-1 and P-SEL levels were significantly higher in patients with PCC participants compared with control subjects at 3 months using the Mann-Whitney U test. We managed to reproduce and validate the findings, emphasizing the importance of collaborative biobanking efforts in enhancing the reproducibility and credibility of Long COVID research outcomes.

中文翻译：

---

使用 Biobanque québécoise de la COVID-19 (BQC-19) 的数据验证 ANG-1 和 P-SEL 作为 COVID-19 后病症的生物标志物

寻求理解和管理 COVID-19 的长期影响（通常称为长期 COVID 或 COVID-19 后病症 (PCC)）仍然是一个活跃的研究领域。最近的研究结果强调血管生成素-1 (ANG-1) 和 p-选择素 (P-SEL) 作为潜在的诊断标记物，但鉴于 COVID-19 生物标记物研究的不一致，验证至关重要。利用 Biobank québécoise de la COVID-19 (BQC19) 生物库，我们分析了 249 名参与者的数据。使用 Mann-Whitney U 检验，3 个月时 PCC 参与者患者的 ANG-1 和 P-SEL 水平均显着高于对照组。我们成功地重现并验证了研究结果，强调了生物样本库合作工作在提高长新冠病毒研究结果的可重复性和可信度方面的重要性。